Announcement for the Purposes of Rule 2.12 of the Irish Takeover Rules

Written by Customer Service on March 27, 2024. Posted in Public Companies.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. BURLINGTON, Mass., March 27, 2024 (GLOBE NEWSWIRE) — Further to the announcement made by Progress Software Corp. (“Progress”) under Rule 2.4 of the Irish Takeover Rules on March 26, 2024, Progress confirms for the purposes of Rule 2.12 of the Irish Takeover Rules that any offer by Progress for MariaDB plc (“MariaDB”) is, or is likely to be, solely in cash. Accordingly, there are no disclosure requirements under Rule 8.1, Rule 8.2 and Rule 8.3 of the Irish Takeover Rules in relation to relevant securities of Progress. There can be no certainty that an offer will be made, or as to the terms on which any offer might be made. A further announcement...

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive pacemaker patients in collaboration with Medtronic, plc (NYSE: MDT) in December 2023 Orchestra BioMed and Terumo remain actively engaged to update operational plans and financial arrangements for Virtue® Sirolimus AngioInfusionTM Balloon (“SAB”) development and commercialization for treatment of coronary and peripheral artery disease Expected runway of cash and cash equivalents and marketable securities, including certain potential future proceeds sufficient into 2H 2026, beyond anticipated BACKBEAT top-line results readout NEW HOPE, Pa., March 27, 2024 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company...

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET BOSTON and ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted recent developments. “2023 was a year of clinical execution across our pipeline, culminating in the recent pre-NDA meeting with the FDA for IkT-001Pro and robust enrollment of untreated Parkinson’s patients in our 201 Trial evaluating Risvodetinib (“Risvo”),” said Dr. Milton H. Werner, President and Chief...

Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

2023 Research & Development Revenue of $18.1 Million Expected to Increase to $28.0 Million in 2024 Commercialization Underway with Revenue Expected in 2H 2024 for DeepView AI®-Burn Indication in the UK On Track for Additional Regulatory Submissions in US and UK for DeepView™ System Burn and Diabetic Foot Ulcer Indications DALLAS, March 27, 2024 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2023”) and full year (“FY 2023”) ended December 31, 2023 and provided an update on its ongoing business activities. “Spectral AI achieved much in 2023, and our progress along multiple fronts has...

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis Successful in vivo LNC platform studies demonstrating (a) the oral delivery of small oligonucleotides with biological activity and (b) the dramatically improved safety of LNC-docetaxel over IV-docetaxel, with similar efficacy, supports the future use of the LNC platform in inflammation and oncology Conference call begins at 4:30 p.m. Eastern time today BEDMINSTER, N.J., March 27, 2024 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical...

Rumble Reports Fourth Quarter and Full Year 2023 Results

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

~ Full Year 2023 Revenue Increased 106% to $81.0 Million ~ ~ Fourth Quarter Average Monthly Active Users Sequentially Increased 16% to 67 Million ~ ~ Achieved Company’s Largest Milestone To-Date with Public Launch of Rumble Cloud ~ LONGBOAT KEY, Fla., March 27, 2024 (GLOBE NEWSWIRE) — Rumble Inc. (Nasdaq: RUM) (“Rumble” or the “Company”), the video sharing platform and cloud services provider, today announced financial results for the fiscal quarter and full year ended December 31, 2023. Q4 2023 and Full Year Key Highlights Revenue for the full year 2023 increased 106% to $81.0 million, compared to $39.4 million for the year ended December 31, 2022. Fourth quarter revenue increased to $20.4 million, compared to $20.0 million in the fourth quarter of 2022, and $18.0 million in the third quarter of 2023. Average...

Gaia Reports Fourth Quarter and Full Year 2023 Results

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

BOULDER, Colo., March 27, 2024 (GLOBE NEWSWIRE) — Gaia, Inc. (NASDAQ: GAIA) (“Gaia” or the “Company”), a conscious media and community company, reported financial results for the fourth quarter and full year ended December 31, 2023. “We continue to build on Gaia’s increasing momentum. The member count grew to 806,000 at the end of the year and we expect to finish the first quarter of 2024 at about 838,000, a good milestone toward our 15% revenue growth target for 2024,” said Jirka Rysavy, Gaia’s Chairman. “The growth in gross profit per employee was the main driver of our significant cashflow improvement.” Gaia CFO Ned Preston commented: “During 2023, the company generated improvement of $4.2 million in operating cash flow and $8.4 million in free cash flow, with our significant increase in annualized gross profit per employee...

Aqua Metals Advances Sierra-ARC Lithium Battery Recycling Campus and Secures Offtake Partnership; Reports Full-Year 2023 Financial Results

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

RENO, Nev., March 27, 2024 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in sustainable lithium-ion battery recycling, today reported financial results for the full-year ended December 31, 2023. Full-Year 2023 Financial and Recent Operational Highlights Operational Established a platform for commercial production by successfully commissioning the Li AquaRefining™ pilot plant and operating the plant for over one year including 24-hour/five-day per week operations at the Company’s Innovation Center, with the recovery of lithium hydroxide and carbonate, nickel, copper, cobalt, and manganese dioxide, and de-risking through pilot operations. Completed an engineering report that included a Life Cycle Analysis (LCA) of Li AquaRefining™ through ICF, an internationally recognized third party, showing an 83%...

The Oncology Institute Reports Fourth Quarter and Full Year 2023 Financial Results and Guidance for 2024

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

CERRITOS, Calif., March 27, 2024 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2023. Recent Operational Highlights Remediated material weakness in Internal Controls over review of Complex Accounting Transactions. Signed full-risk capitated contract in South Florida, effective January 1, 2024 and have now successfully onboarded the membership and the IPA providers. Acquired and launched our California-based pharmacy in December and have already completed over 1,300 specialty medication fills. Jeremy Castle enjoyed his first full quarter as our new Chief Operating Officer. Hired 7 new providers in the quarter and ended the year...

PLBY Group Reports Fourth Quarter & Full Year 2023 Financial Results

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

Q4 Revenue of $39.4 Million, Net Loss of $3.8 Million & Adjusted EBITDA of $1.1 Million Amends Credit Facility to Eliminate Total Net Leverage Covenant Until Q2 2026 Company to Hold Question-and-Answer Session at 4:30 pm ET Today LOS ANGELES, March 27, 2024 (GLOBE NEWSWIRE) — PLBY Group, Inc. (NASDAQ: PLBY) (“PLBY Group” or the “Company”), a leading pleasure and leisure lifestyle company and owner of Playboy, one of the most recognizable and iconic brands in the world, today provided financial results for the fourth quarter and full year ended December 31, 2023. Comments from Ben Kohn, Chief Executive Officer of PLBY Group “In 2023, we worked on five main goals. First, restructure the Company and move to a capital-light business model; second, reduce overhead; third, stabilize and reposition Honey Birdette back to a premium...

Day: March 27, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice